eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
3/2008
vol. 7
 
Share:
Send email
Share:
abstract:

Local oestrogen therapy and the risk of neoplasmatic disease

Tomasz Rechberger
,
Marta Kokot
,
Aleksandra Bartuzi
,
Andrzej Wróbel

Przegląd Menopauzalny 2008; 3: 123–126
Online publish date: 2008/07/07
View full text Get citation
 
Local oestrogen therapy is regarded as the therapeutic standard in the treatment of urogenital atrophy. In women treated previously due to non-hormone-dependent tumours, urogenital atrophy treatment is similar to that in patients without cancer in the past with the exception of those who were subjected to radiotherapy of the pelvis. In this group local, low-dose oestrogen therapy is indicated in order to stimulate regeneration of epithelium, improvement of flexibility and lubrication of the vaginal wall. The first line of treatment in patients suffering from urogenital atrophy with hormone-dependent tumours in anamnesis consists of vaginal lubricants and moisturizers, but local oestrogen could also be considered after consultation with an oncologist. On the other hand, because of the fact that systemic absorption of oestrogens from low-dose vaginal tablets is minimal, it may be supposed with high probability that the possible promotional effect of neoplastic recurrence would be minimal.
keywords:

atrophy, local oestrogen treatment, risk of neoplastic disease
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.